New drug combo aims to protect failing kidneys
NCT ID NCT06942910
Summary
This study is testing whether adding a new drug called zibotentan to an existing kidney drug (dapagliflozin) works better than dapagliflozin alone. It aims to see if the combination can better reduce the amount of protein leaking into the urine, which is a sign of kidney damage. The trial will involve 224 adults with chronic kidney disease and will last for about 12 weeks of treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE WITH HIGH PROTEINURIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGAramil, 624002, Russia
-
Research Site
SUSPENDEDIzhevsk, 426061, Russia
-
Research Site
RECRUITINGMoscow, 111539, Russia
-
Research Site
RECRUITINGMoscow, 117036, Russia
-
Research Site
RECRUITINGMoscow, 129327, Russia
-
Research Site
RECRUITINGPerm, 614000, Russia
-
Research Site
RECRUITINGSaint Petersburg, 195067, Russia
-
Research Site
RECRUITINGSaratov, 410053, Russia
-
Research Site
RECRUITINGSaratov, 410054, Russia
-
Research Site
RECRUITINGYaroslavl, 150062, Russia
Conditions
Explore the condition pages connected to this study.